InMed Pharmaceuticals, A Cannabinoid-Focused Company, Sponsored Benzinga's Cannabis Capital Conference

InMed Pharmaceuticals (NASDAQ: INM) is a global leader in researching, developing, manufacturing and commercializing rare cannabinoids and cannabinoid analogs. The company is focused on the therapeutic benefits of cannabinol (CBN) as a pipeline of cannabinoid-based drug candidates for the treatment of diseases with high unmet medical needs. 

InMed is a clinical-stage company with expertise in the development of biosynthesis, IP, manufacturing and GMP scale-up methodologies. In addition to their innovative research in CBN, InMed Pharmaceuticals is also widely known for its Foundations™ technology – a pediatric, patient-friendly cannabinoid delivery system.

Interested in learning more about the Benzinga Cannabis Capital Conference? Get more information here.